Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insmed (INSM) Accumulated Expenses (2016 - 2026)

Insmed's Accumulated Expenses history spans 17 years, with the latest figure at $162.1 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 1381.92% to $162.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $162.1 million through Mar 2026, up 1381.92% year-over-year, with the annual reading at $17.1 million for FY2025, 89.55% down from the prior year.
  • Accumulated Expenses came in at $162.1 million for Q1 2026, up from $17.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $163.7 million in Q4 2024 to a low of $6.0 million in Q3 2023.
  • The 5-year median for Accumulated Expenses is $37.9 million (2022), against an average of $77.0 million.
  • Year-over-year, Accumulated Expenses plummeted 95.21% in 2024 and then surged 1381.92% in 2026.
  • Insmed's Accumulated Expenses stood at $151.5 million in 2022, then increased by 4.37% to $158.2 million in 2023, then grew by 3.48% to $163.7 million in 2024, then crashed by 89.55% to $17.1 million in 2025, then skyrocketed by 848.11% to $162.1 million in 2026.
  • Per Business Quant, the three most recent readings for INSM's Accumulated Expenses are $162.1 million (Q1 2026), $17.1 million (Q4 2025), and $9.4 million (Q3 2025).